PDCD1 and neoplasm: Our work provides a platform that can deliver both NIL-IM-Lip and a PD-1 mAb into hot tumours, cold tumours and LNs to enhance immunotherapy, which greatly promotes the efficacy of the PD-1 mAb and shows great clinical application prospects.